Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...

Bernstein initiated coverage of Biogen Inc (NASDAQ:BIIB) with a “Market-Perform” rating and a price target of $160 as it ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

Bernstein launched its coverage of Biogen (NASDAQ:BIIB) on Tuesday with a Market Perform recommendation ahead of its Q4 earnings release this week, citing a difficult sales trajectory for the ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

Bernstein initiated coverage of Biogen (BIIB) with a Market Perform rating and $160 price target For the past five years, Biogen “has lived ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

Key contributors included LEQEMBI with a 28.1 billion yen increase, Lenvima with 24.9 billion yen growth, and Dayvigo up by 9.3 billion yen. Naito emphasized significant milestones for LEQEMBI ...

Investing.com -- BioArctic AB (STO:BIOA B)股价上涨4.8%，此前其合作伙伴Eisai公布的Leqembi销售数据超出市场预期。该阿尔茨海默病治疗药物在2024年第四季度实现销售额133亿日元，高于Visible Alpha预测的117亿日元。